RxDoctor Payments Data

Kelli Koons, MD

Internal Medicine · Shawnee, OKNPI 1134169295

Payments from drug & device makers

$2,452in general payments, 2019–2025

Across 154 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$271
  • Lilly USA, LLC$261
  • Pfizer$163
  • Amgen$128
  • Corium, LLC$58
  • plus $540 from 18 others

What the payments were for

  • Food & beverage$2,39197%
  • Education$623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,452 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$217,523
Medicare patients
1,769
Services billed
7,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$136,767
EliquisApixaban101$76,475
JanuviaSitagliptin Phosphate81$59,879
JardianceEmpagliflozin63$46,213
XareltoRivaroxaban66$36,932
FarxigaDapagliflozin Propanediol31$33,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$32,774
VraylarCariprazine Hcl20$29,141
JanumetSitagliptin Phos/Metformin Hcl16$18,746
EntrestoSacubitril/Valsartan14$15,281
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen438$13,487
LinzessLinaclotide17$9,070
Breo ElliptaFluticasone/Vilanterol16$7,817
Xtampza ErOxycodone Myristate12$6,503
Gabapentin416$5,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$48$136,767132 claims
PfizerEliquis$163$76,475101 claims
Boehringer IngelheimJardiance$30$46,21363 claims
GSKTrelegy Ellipta, Breo Ellipta$38$40,59158 claims
AbbVieVraylar, Linzess$1,031$38,21137 claims
AstraZenecaFarxiga$271$33,42531 claims
NovartisEntresto$30$15,28114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Shawnee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →